Antibody‒cell conjugates: A novel "off-the-shelf" modality bridging ADCs and CAR-T for cancer immunotherapy.
- 1Yangtze River Delta Center for Drug Evaluation and Inspection of The National Medical Products Administration, Shanghai 201210, China.
- 2Department of Cardiology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China.
- 3Department of Pulmonary and Critical Care Medicine, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200120, China.
Abstract
Antibody‒cell conjugates (ACCs) represent a promising therapeutic strategy emerging in the biopharmaceutical industry to overcome the limitations of current immunotherapies. ACCs constitute a novel class of living drugs developed by anchoring functional antibodies onto the surface of living cells via specific linkers or conjugation methods. These carrier cells encompass both immune effector cells (such as Natural Killer cells, γδ T cells, and activated T cells) and non-immune cells (such as erythrocytes and platelets). Distinct from genetic engineering, ACCs directly modify the cell surface using chemical biology, enzymatic catalysis, or physical assembly, thereby endowing cells with precise tumor-targeting capabilities while preserving their intrinsic biological functions. This technology facilitates the scalable production of "off-the-shelf" therapeutics and has shown promising potential in treating both hematological malignancies and refractory solid tumors with a superior safety profile. This review systematically examines the current construction strategies and carrier cell selection for ACCs, covering both immune effector cells and non-immune carrier cells, and discusses the clinical progress, key challenges, and future directions.
Related
- Combination of antibody–drug conjugates with immunotherapy: a new paradigm in cancer treatment
- A New Era of Treatment Sequencing in Platinum-Resistant Ovarian Cancer: Integrating Immunotherapy, Antibody-Drug Conjugates, and Targeted Therapies.
- Efficacy and safety of antibody-drug conjugates in advanced small cell lung cancer: a systematic review and single-arm meta-analysis of prospective clinical trials
- Efficacy and safety of antibody-drug conjugates in pretreated HER2-positive advanced breast cancer: a network meta-analysis of randomized controlled trials
- Emerging antibody–drug conjugates in lung cancer: highlights from the 2026 ASCO Annual Meeting
BibTeX
@article{dai2026antibodycell,
title = {{Antibody‒cell conjugates: A novel "off-the-shelf" modality bridging ADCs and CAR-T for cancer immunotherapy.}},
author = {Yifei Dai and Yujia Xie and Xiaojuan Ma and Dong Zhang and Jiao Yang and Kequan Lin and Aiping Chen and Weijie Qiang},
journal = {Acta pharmaceutica Sinica. B},
year = {2026},
month = jul,
doi = {10.1016/j.apsb.2026.07.034},
url = {https://europepmc.org/article/MED/42948354},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Antibody‒cell conjugates: A novel "off-the-shelf" modality bridging ADCs and CAR-T for cancer immunotherapy.
AU - Yifei Dai
AU - Yujia Xie
AU - Xiaojuan Ma
AU - Dong Zhang
AU - Jiao Yang
AU - Kequan Lin
AU - Aiping Chen
AU - Weijie Qiang
PY - 2026
DA - 2026/07/25
JO - Acta pharmaceutica Sinica. B
DO - 10.1016/j.apsb.2026.07.034
UR - https://europepmc.org/article/MED/42948354
AB - Antibody‒cell conjugates (ACCs) represent a promising therapeutic strategy emerging in the biopharmaceutical industry to overcome the limitations of current immunotherapies. ACCs constitute a novel class of living drugs developed by anchoring functional antibodies onto the surface of living cells via specific linkers or conjugation methods. These carrier cells encompass both immune effector cells (such as Natural Killer cells, γδ T cells, and activated T cells) and non-immune cells (such as erythrocytes and platelets). Distinct from genetic engineering, ACCs directly modify the cell surface using chemical biology, enzymatic catalysis, or physical assembly, thereby endowing cells with precise tumor-targeting capabilities while preserving their intrinsic biological functions. This technology facilitates the scalable production of "off-the-shelf" therapeutics and has shown promising potential in treating both hematological malignancies and refractory solid tumors with a superior safety profile. This review systematically examines the current construction strategies and carrier cell selection for ACCs, covering both immune effector cells and non-immune carrier cells, and discusses the clinical progress, key challenges, and future directions.
SN - 2211-3835
SN - 2211-3843
ER -